Results 11 to 20 of about 1,729,719 (389)

A four-month gatifloxacin-containing regimen for treating tuberculosis. [PDF]

New England Journal of Medicine, 2014
BACKGROUND Shortening the course of treatment for tuberculosis would be a major improvement for case management and disease control. This phase 3 trial assessed the efficacy and safety of a 4-month gatifloxacin-containing regimen for treating rifampin ...
C. Merle, K. Fielding, O. Sow, M. Gninafon, M. B. Lo, T. Mthiyane, J. Odhiambo, E. Amukoye, B. Bah, F. Kassa, A. N’Diaye, R. Rustomjee, B. D. de Jong, J. Horton, C. Perronne, C. Sismanidis, Olivier Lapujade, P. Olliaro, C. Lienhardt   +18 more
semanticscholar   +3 more sources

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.

New England Journal of Medicine, 2022
BACKGROUND In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed.
Bern-Thomas Nyang'wa, Catherine Berry, Emil Kazounis, I. Motta, N. Parpieva, Z. Tigay, V. Solodovnikova, I. Liverko, R. Moodliar, M. Dodd, N. Ngubane, M. Rassool, T. McHugh, M. Spigelman, D. Moore, K. Ritmeijer, P. D. du Cros, Katherine L. Fielding   +17 more
semanticscholar   +1 more source

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Clinical Infectious Diseases, 2020
Background The 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) is indicated for treatment-naive adults with human immunodeficiency virus type 1 (HIV-1).
J. van Wyk, F. Ajana, F. Bisshop, S. De Wit, O. Osiyemi, J. Portilla Sogorb, J. Routy, C. Wyen, M. Ait‐Khaled, M. Nascimento, K. Pappa, Ruolan Wang, Jonathan Wright, A. Tenorio, B. Wynne, M. Aboud, M. Gartland, Kimberly Smith   +17 more
semanticscholar   +1 more source

Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials

Annals of Medicine, 2023
Background Multiple myeloma (MM) is an incurable malignancy. Venetoclax (VEN) shows a meaningful effect in MM patients who are relapsed or refractory (RR) to previous standard therapies.Objective This study aimed to assess the efficacy and safety of VEN ...
Wei He, Fang He, Huixian Hu
doaj   +1 more source

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

Journal of Clinical Oncology, 2020
PURPOSE Reduced-intensity conditioning (RIC) regimens have extended the curative potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid leukemia (AML) and myelodysplasia (MDS) but are associated with a high risk of
C. Craddock, Aimee E Jackson, J. Loke, S. Siddique, A. Hodgkinson, J. Mason, Georgia Andrew, S. Nagra, R. Malladi, A. Peniket, M. Gilleece, R. Salim, E. Tholouli, V. Potter, C. Crawley, K. Wheatley, R. Protheroe, P. Vyas, A. Hunter, A. Parker, K. WIlson, J. Pavlů, J. Byrne, R. Dillon, N. Khan, N. McCarthy, S. Freeman   +26 more
semanticscholar   +1 more source

Idelalisib and Rituximab Regimen [PDF]

Hospital Pharmacy, 2017
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
A. Kacee Barnett, Dominic A. Solimando, J. Aubrey Waddell   +2 more
openaire   +3 more sources

Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

New England Journal of Medicine, 2000
BACKGROUND Registry data on patients with type 1 diabetes mellitus who undergo pancreatic islet transplantation indicate that only 8 percent are free of the need for insulin therapy at one year.
A. M. Shapiro, J. Lakey, E. Ryan, G. Korbutt, E. Toth, G. Warnock, N. Kneteman, R. Rajotte   +7 more
semanticscholar   +1 more source

Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. [PDF]

, 2019
INTRODUCTION: 2018 World Health Organization (WHO) guidelines for the treatment of isoniazid (H)-resistant (Hr) tuberculosis recommend a four-drug regimen: rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx), with or without H ([H]RZE-
Abbara, A, Abubakar, I, Alexander, E, Baker, LV, Barrett, JC, Booth, H, Bothamley, GH, Burgess, H, Cosgrove, C, Creer, DD, Davidson, JA, Dunleavy, A, Francis, M, Grp, LINH-RTBS, Gupta, U, Hamid, S, Harris, RJ, Haselden, BM, Holden, E, Kahr, V, Kon, OM, Kunst, H, Lalor, MK, Lipman, MC, Loebinger, MR, Loutet, MG, Lozewicz, S, Lynn, W, McHugh, TD, Milburn, HJ, Mohiyuddin, T, Palchaudhuri, P, Perrin, FM, Phillips, PPJ, Rahman, A, Schmok, E, Soobratty, MR, Stagg, HR, Taylor, L   +38 more
core   +3 more sources

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Blood, 2019
Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams.
W. Stock, S. Luger, A. Advani, Jun Yin, R. Harvey, C. Mullighan, C. Willman, N. Fulton, K. Laumann, G. Malnassy, E. Paietta, E. Parker, S. Geyer, K. Mrózek, C. Bloomfield, B. Sanford, G. Marcucci, M. Liedtke, D. Claxton, M. Foster, J. Bogart, J. Grecula, F. Appelbaum, H. Erba, M. Litzow, M. Tallman, R. Stone, R. Larson   +27 more
semanticscholar   +1 more source

Multicenter, randomized study to optimize bowel for colon capsule endoscopy [PDF]

, 2017
AIM To assess the cleansing efficacy and safety of a new Colon capsule endoscopy (CCE) bowel preparation regimen. METHODS This was a multicenter, prospective, randomized, controlled study comparing two CCE regimens. Subjects were asymptomatic and average
Burch, Wilmot C., Jr, Kashyap, Pankaj K., Kastenberg, David, Papageorgiou, Neophytos, Pound, David C., Rex, Douglas K., Romeo, David P., Sainz, Ignacio Fernández-Urien, Sokach, Carly E.   +8 more
core   +2 more sources